Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a ...

Here’s what you missed this week on Managed Healthcare Executive. Each Sunday we feature a highlight reel of various articles posted on our website that week.

As a medical student, I remember seeing what RA looked like before we had effective medications such as methotrexate and TNF ...

Biosimilars show comparable safety with Humira among new users with psoriasis in a multinational cohort study, but ...

AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...

Policy experts punched holes in drug companies' claims that the Medicare Drug Price Negotiation Program will stunt innovation ...

The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...

The Institute for Clinical and Economic Review flagged five drugs whose prices were raised in 2023 with no evidence to support it. Meanwhile, the makers of these drugs have been reporting double-digit ...

Medicare typically covers Humira through Part D and Part C. But since Humira is considered a specialty drug, it can be expensive, though many factors play into the cost you’ll pay. You may be ...

AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Investors looking for a way to pump up their passive income streams want to turn their attention toward the pharmaceutical ...